CHICAGO (November 4, 2009)––Researchers at Fox Chase Cancer Center found that radiation treatment for women who had a lumpectomy for early-stage breast cancer can be safely reduced to four weeks, instead of the usual six to seven weeks, by delivering a higher daily dose––greatly reducing the length of treatment time. The five-year results of the phase II study will be presented today at the annual meeting of the American Society for Radiation Oncology.
The study showed that treatment time can be shortened from the historical six to seven weeks to just four weeks using IMRT (intensity-modulated radiation therapy), a highly sophisticated system of delivering external-beam radiation. This system uses advanced computer optimized planning and radiation delivery techniques that create more optimal dose distributions, greater sparing of the skin and lower doses to organs such as lung and heart––thus reducing potential side effects.
"When delivering high doses of radiation, we have to consider the level of side effects and the cosmetic result," explained Gary Freedman, M.D., radiation oncologist at Fox Chase. "In this phase II study, women reported acceptable side effects that were no different than would be expected from a usual, more prolonged length of treatment. In addition, with long term follow-up we see cure rates and cosmetic results that are similar to a longer six-week treatment course."
Using IMRT, this study examined the delivery of a higher daily dose of radiation over four weeks (versus a lower dose over six to seven weeks). Another way of reducing treatment length was by incorporating a "boost" into the same four weeks. The lumpectomy site where the tumor was removed is usually treated with a high-dose radiation "boost." The standard "boost" is typically administered after the five weeks of whole breast irradiation and can add another one to two weeks to the treatment time.
Freedman and his colleagues demonstrated that in addition to safely increasing the dose to the whole breast during the four-week period, it is possible to deliver the "boost" concurrently, eliminating the extra two weeks.
"This more accelerated treatment regimen should be an option for women who want to be treated in a shorter period of time," says Freedman. "This may particularly appeal to women who drive a long distance for radiation, have busy schedules at home or work, or have a large insurance co-pay for each daily radiation treatment."
Freedman cautioned that this treatment schedule may not be for all women. "There may be patients who are uncomfortable with the idea of an accelerated treatment and want to be treated with a more conventional six to seven week course of treatment," he says. "In addition, we need more research to determine which women are ideal candidates for this treatment because of differences in anatomy or other treatments for their breast cancer."
The study included 75 women treated with 2.25 Gy for 20 days (versus 2 Gy per day with conventional therapy) and a 2.8 Gy boost concurrently (versus sequentially delivering the boost after whole breast irradiation). The risk of recurrence within five years in the treated breast was low–.4%––which compares favorably to results with conventional radiation. In addition, patients and their physicians considered the cosmetic results good or excellent in most women.
Fox Chase Cancer Center is one of the leading cancer research and treatments centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's web site at www.fccc.edu or call 1-888-FOX-CHASE or 1-888-369-2427.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.